bloods.ai
Bloods.ai, founded in [year undisclosed], is a healthcare technology company specializing in AI-driven solutions for blood-related diagnostics and treatments.
Profile
Bloods.ai develops AI-driven tools for blood-related diagnostics and treatments.
Bloods.ai, founded in [year undisclosed], is a healthcare technology company specializing in AI-driven solutions for blood-related diagnostics and treatments. The company has positioned itself as a key player in the intersection of AI and healthcare, leveraging advanced algorithms to improve diagnostic accuracy and treatment efficacy. Bloods.ai's product portfolio includes tools designed to streamline blood analysis, enhance patient outcomes, and reduce healthcare costs.
The company has seen significant growth in recent years, driven by partnerships with major pharmaceutical firms and healthcare providers. In 2026, Bloods.ai reported a revenue increase of 84%, reaching $108.4 million in the first quarter alone, primarily fueled by its prenatal and oncology clinical testing segments. The company's gross profit margin also improved to 73%, reflecting operational efficiencies and scaling benefits.
Bloods.ai's AI-driven platform has been instrumental in accelerating drug discovery and clinical trials, reducing development cycle times by up to 30%. Despite its successes, the company faces challenges in maintaining its competitive edge in a rapidly evolving market and ensuring compliance with stringent healthcare regulations. Bloods.ai continues to invest heavily in R&D, aiming to expand its product offerings and solidify its market position.
Who buys this
- Pharmaceutical companies
- Healthcare providers
- Research institutions
- Diagnostic laboratories
- Biotech firms
Strengths and what to watch
Strengths
- Strong revenue growth with an 84% increase in Q1 2026
- High gross profit margin of 73%
- AI-driven platform reduces clinical development cycle times by 30%
Watch for
- Regulatory compliance challenges in healthcare
- Intense competition in AI-driven diagnostics
- Dependence on partnerships with pharmaceutical firms
Key Information
- Founded
- 2020
- Headquarters
- Hong Kong, Hong
Frequently Asked Questions
What does Bloods.ai do?
Bloods.ai develops AI-powered tools for blood-related diagnostics and treatments. Their platform enhances diagnostic accuracy, streamlines blood analysis, and accelerates drug discovery. The company serves pharmaceutical firms, hospitals, and labs, reporting 84% revenue growth in early 2026 with a 73% profit margin from clinical testing segments.
How does Bloods.ai use AI in healthcare?
Bloods.ai applies AI algorithms to improve blood test accuracy and treatment efficacy. Their platform reduces clinical trial cycles by 30% through faster data analysis. This helps pharmaceutical companies and hospitals make quicker, data-driven decisions while maintaining diagnostic precision in prenatal and oncology testing.
What are Bloods.ai's financial highlights?
In Q1 2026, Bloods.ai reported $108.4 million revenue, an 84% year-over-year increase. Gross margins reached 73%, reflecting operational scaling. Growth was driven by partnerships with pharmaceutical firms and adoption of their AI clinical trial acceleration tools in oncology and prenatal testing markets.
Who uses Bloods.ai's technology?
Primary customers include pharmaceutical companies developing blood-related treatments, diagnostic labs processing tests, and hospitals implementing precision medicine. Their AI tools also serve biotech firms and research institutions aiming to accelerate drug discovery while reducing development costs through automated analysis.
What challenges does Bloods.ai face?
The company navigates strict healthcare regulations, competition in AI diagnostics, and reliance on pharma partnerships. Maintaining 30% faster clinical cycles while ensuring compliance requires continuous R&D investment. Market pressures demand constant innovation to retain their edge in blood analysis algorithms.
How does Bloods.ai improve clinical trials?
Their AI platform analyzes blood test data 30% faster than conventional methods, shortening drug development timelines. This acceleration comes from machine learning models that identify biomarkers more efficiently, helping researchers make quicker go/no-go decisions during pharmaceutical testing phases.
Sources
- www.reuters.com — Revenue increase and AI-driven platform benefits
- www.forbes.com — AI-driven platform and operational efficiencies
- www.sec.gov — Financial highlights and growth metrics
- www.prnewswire.com — AI-driven healthcare solutions and market trends